PMID- 26796520
OWN - NLM
STAT- MEDLINE
DCOM- 20161011
LR  - 20190221
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 11
DP  - 2016 Jan 22
TI  - SSTR2 promoter hypermethylation is associated with the risk and progression of 
      laryngeal squamous cell carcinoma in males.
PG  - 10
LID - 10.1186/s13000-016-0461-y [doi]
LID - 10
AB  - BACKGROUND: Somatostatin receptor 2 (SSTR2) encodes somatostatin receptor that 
      can inhibit the cell proliferation of solid tumors. Promoter hypermethylation is 
      likely to silence the expression of SSTR2. The goal of our study was to 
      investigate the association between SSTR2 promoter methylation and the risk and 
      progression of laryngeal carcinoma. METHODS: In the current study, tumor tissues 
      and their adjacent non-tumor tissues were collected from a total of 87 laryngeal 
      squamous cell carcinoma (LSCC) male patients. DNA methylation levels of nine 
      SSTR2 promoter CpGs were measured using the bisulphite pyrosequencing technology. 
      RESULTS: Our results revealed that there was a significantly increased SSTR2 
      promoter methylation in LSCC tissues than in their adjacent non-cancerous tissues 
      (adjusted P = 0.003). Breakdown analysis by age indicated that the significant 
      association was mainly contributed by patients younger than 60 (adjusted 
      P = 0.039) but not in patients older than 60. Meanwhile, the significant 
      association was observed in the patients with moderately (adjusted P = 0.037) and 
      well differentiated tissues (adjusted P = 0.028), as well as the patients with 
      histological stage IV (adjusted P = 0.031). Multivariate Cox analysis suggested 
      that SSTR2 promoter methylation was an independent prognostic factor of LSCC 
      (HR = 1.127, 95 % CI = 1.034-1.228). CONCLUSIONS: In conclusion, SSTR2 promoter 
      hypermethylation might be associated with the risk and progression of LSCC in 
      males.
FAU - Shen, Zhisen
AU  - Shen Z
AD  - Department of Otorhinolaryngology (Head and Neck Surgery), Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, 315040, China. szs7216@163.com.
FAU - Chen, Xiaoying
AU  - Chen X
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. cxywzmc@163.com.
FAU - Li, Qun
AU  - Li Q
AD  - Department of Otorhinolaryngology (Head and Neck Surgery), Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, 315040, China. 704793521@qq.com.
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. 704793521@qq.com.
FAU - Zhou, Chongchang
AU  - Zhou C
AD  - Department of Otorhinolaryngology (Head and Neck Surgery), Lihuili Hospital of 
      Ningbo University, Ningbo, Zhejiang, 315040, China. 1271692704@qq.com.
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. 1271692704@qq.com.
FAU - Li, Jinyun
AU  - Li J
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. woodrenemma@163.com.
FAU - Ye, Huadan
AU  - Ye H
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. yehuadan@163.com.
FAU - Duan, Shiwei
AU  - Duan S
AD  - Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo 
      University, Ningbo, Zhejiang, 315211, China. duanshiwei@nbu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160122
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Somatostatin)
RN  - 0 (SSTR2 protein, human)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Differentiation
MH  - CpG Islands
MH  - *DNA Methylation
MH  - Disease Progression
MH  - Epigenesis, Genetic
MH  - Head and Neck Neoplasms/*genetics/pathology
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - *Promoter Regions, Genetic
MH  - Proportional Hazards Models
MH  - Receptors, Somatostatin/*genetics
MH  - Risk Factors
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC4722764
EDAT- 2016/01/23 06:00
MHDA- 2016/10/12 06:00
PMCR- 2016/01/22
CRDT- 2016/01/23 06:00
PHST- 2015/11/04 00:00 [received]
PHST- 2016/01/14 00:00 [accepted]
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/10/12 06:00 [medline]
PHST- 2016/01/22 00:00 [pmc-release]
AID - 10.1186/s13000-016-0461-y [pii]
AID - 461 [pii]
AID - 10.1186/s13000-016-0461-y [doi]
PST - epublish
SO  - Diagn Pathol. 2016 Jan 22;11:10. doi: 10.1186/s13000-016-0461-y.